Citations 2
Vascular Diseases in Women: Do Women Suffer from Them Differently?
Farkas, Katalin , Stanek, Agata , Zbinden, Stéphanie, Borea, Barbara, Ciurica, Simina, Moore, Vanessa , Maguire, Peggy, Alajar, Elaine, Marcoccia, Antonella , Erer, Dilek , Casanegra, Ana I. , Sharebiani, Hiva , Sprynger, Muriel , Kavousi, Maryam , Catalano, M. , Casanegra, Ana I , Sharebiani, Hiva , Sprynger, Muriel , Kavousi, Maryam , Catalano, Mariella , Farkas, Katalin , Stanek, Agata , Ciurică, Simina , Moore, Vanessa, Abola, Maria Teresa B.
Journal of Clinical Medicine | February 15, 2024 | Volume: 13 | Issue: 4 | Pages: 1108
According to the World Health Organization, cardiovascular disease (CVD) is the leading cause of death among women worldwide, yet its magnitude is often underestimated. Biological and gender differences affect health, diagnosis, and healthcare in numerous ways. The lack of sex and gender awareness in health research and healthcare is an ongoing issue that affects not only research but also treatment and outcomes. The importance of recognizing the impacts of both sex and gender on health and of knowing the differences between the two in healthcare is beginning to gain ground. There is more appreciation of the roles that biological differences (sex) and sociocultural power structures (gender) have, and both sex and gender affect health behavior, the development of diseases, their diagnosis, management, and the long-term effects of an illness. An important issue is the knowledge and awareness of women about vascular diseases. The risk of cardiovascular events is drastically underestimated by women themselves, as well as by those around them. The purpose of this review is to draw attention to improving the medical care and treatment of women with vascular diseases.
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
Gerotziafas, Grigoris , Catalano, Mariella, Pécsvárady, Zsolt, Wautrecht, Jean Claude, Olinic, Dan-Mircea , Farkas, Katalin , Elalamy, Ismaı̈l , Fareed, Jawed , Papageorgiou, Chryssa, Arellano, Rosella S., Agathagelou, Petros, Antic, Darco, Auad, Luciana, Banfić, Ljiljana , Bartolomew, John R., Benczúr, Béla , Bernardo, M., Boccardo, Francesco M., Cifkova, Renate, Marchi, Sergio De , Dimakakos, Evangelos , Dimitrov, Gabriel, Edmonds, Michael , Nazar, Essam Abo El, Erer, Dilek , Esponda, Omar L. , Gschwandtner, Michael E., Gu, Yongquan , Heinzmann, Mónica, Hamadé, A. , Jatoi, Noor-Ahmed, Karahan, Oğuz , Karplus, Thomas E., Klein‐Weigel, Peter, Kolossváry, Endre , Kozak, Matija, Lefkou, Eleftheria , Lessiani, Gianfranco , Marcoccia, Antonella , Marshang, Peter, Marakomichelakis, George , Matuška, Jiří , Moraglia, Luc, Pillon, Sergio , Poredoš, Pavel , Salvador, David Raymund K., Schlager, Oliver , Schernthaner, G. , Sieron, Alexander, Spaak, Jonas , Spyropoulos, Alex C. , Stanek, Agata , Štvrtinová, Viera, Tafur, Alfonso , Dreden, Patrick Van , Vardas, Panagiotis E., Vasić, Dragan , Wennberg, Paul W. , Zhai, Zhenguo , Committee, Scientific Reviewer, Catalano, M. , Gerotziafas, Grigoris T , Wennberg, Paul, Catalano, Mariella , Dimakakos, Evangelos , Farkas, Katalin , Stanek, Agata , Colgan, Mary Paula , Fazeli, Bahare , Falanga, Anna , Cosmi, Benilde , Dimopoulos, Meletios Α. , Durand‐Zaleski, Isabelle , Gresele, Paolo , Hamburg, Naomi M. , Karetová, Debora , Liew, Aaron , Marschang, Peter , Prior, Manlio , Sprynger, Muriel , Šuput, Dušan , Szuba, Andrzej , Vardas, Panagiotis E., Vikkula, Miikka , Committee, Scientific Reviewer
Thrombosis and Haemostasis | September 13, 2020 | Volume: 120 | Issue: 12 | Pages: 1597-1628
AbstractCOVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.